Developments Aridis Pharma gets EMA orphan drug designation for CF drug Aridis Pharmaceuticals (NASDAQ:ARDS) received European Medicines Agency (EMA) orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF). AR-501 is an inhaled... July 19, 2019